# Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

> **NCT06952452** · PHASE3 · RECRUITING · sponsor: **Parc de Salut Mar** · enrollment: 630 (estimated)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Ranibizumab Ophthalmic

## Key facts

- **NCT ID:** NCT06952452
- **Lead sponsor:** Parc de Salut Mar
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-18
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 630 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06952452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06952452, "Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06952452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*